The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
Abstract
PURPOSE: To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Stage IIIB/IV NSCLC patients were randomized to arm A (four cycles of carboplatin at an area under the curve of 6 and paclitaxel 200 mg/m(2) every 21 days) or arm B (continuous treatment with carboplatin/paclitaxel until progression). At progression, all patients on both arms were to receive second-line weekly paclitaxel at 80 mg/m(2)/wk. The primary end points were survival and quality of life (QOL). RESULTS: Two hundred thirty patients were randomized. Fifty-seven percent of arm A patients completed four courses of therapy. In the 116 arm B patients, the median number of cycles delivered was four (range, zero to 19 cycles). Forty-two percent received five or more cycles; 18% received eight or more cycles. Overall response rates were 22% and 24% for arms A and B, respectively (P =.80). Median survival time and 1-year survival rates were 6.6 months and 28% for arm A and 8.5 months and 34% for arm B, respectively (log-rank P =.63). Rates of hematologic and nonhematologic toxicity were similar between the two arms, except for neuropathy. The rate of grade 2 to 4 neuropathy increased from 19.9% (95% confidence interval [CI], 13.6% to 26.2%) at cycle 4 to 43% (95% CI, 28.6% to 57.4%) at cycle 8. There were no differences in QOL. Only 45% of patients received second-line therapy (42% in arm A v 47% in arm B, P =.42). CONCLUSION: This study shows no overall benefit in survival, response rates, or QOL to continuing treatment with carboplatin/paclitaxel beyond four cycles in advanced NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,181
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Le Chevalier, T., Brisgand, D., Douillard, J. Y., Pujol, J. L., Alberola, V, Monnier, A., Riviere, A., Lianes, P., Chomy, P., & Cigolari, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.360 · Cited by 811
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Cardenal, F., López-Cabrerizo, M. P., Antón, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., García, M., Lianes, P., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.12 · Cited by 471
Bunn, P. A., & Kelly, K. L. (1998) · PubMed · Cited by 400
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Lung cancer: Biology and treatment options
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y.-W., & Buchanan, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,014
Multidisciplinary Management of Lung Cancer
Spira, A., & Ettinger, D. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035536 · Cited by 922
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Ganti, A. K. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 730
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
Stupp, R., Hegi, M. E., Gilbert, M. R., & Chakravarti, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8554 · Cited by 529
Lung cancer: New biological insights and recent therapeutic advances
Ramalingam, S. S., Owonikoko, T. K., & Khuri, F. R. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20102 · Cited by 471
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulières, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 428
Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., Chen, R., Hristova-Kazmierski, M., Treat, J., Obasaju, C. K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1405 · Cited by 418
Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 370
Self-citationSmit, E. F., van Meerbeeck, J. P. A. M., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.195 · Cited by 351
Ettinger, D. S., Akerley, W., Borghaei, H., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K. P., Govindan, R., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0130 · Cited by 349
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Ramalingam, S., & Belani, C. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s1-5 · Cited by 333
Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N., Ciuleanu, T., Cucevic, B., Gyurkovits, K., Ulsperger, E., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.006 · Cited by 320
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Bibby, A. C., Tsim, S., Kanellakis, N., Ball, H., Talbot, D. C., Blyth, K. G., Maskell, N. A., & Psallidas, I. (2016) · European Respiratory Review · doi:10.1183/16000617.0063-2016 · Cited by 316
Grønberg, B. H., Bremnes, R. M., Fløtten, Ø., Amundsen, T., Brunsvig, P. F., Hjelde, H. H., Kaasa, S., von Plessen, C., Stornes, F., Tollåli, T., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9114 · Cited by 288
Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. A. (2003) · Cancer · doi:10.1002/cncr.11578 · Cited by 286
Self-citationGiaccone, G., Bazhenova, L. A., Nemunaitis, J., Tan, M., Juhász, E., Ramlau, R., van den Heuvel, M. M., Lal, R., Kloecker, G. H., Eaton, K. D., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.035 · Cited by 279
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Rivera, E., & Cianfrocca, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2607-5 · Cited by 159
“As an example, in a phase III trial of patients with advanced non-small cell lung cancer, those receiving firstline paclitaxel plus carboplatin demonstrated increased rates of peripheral neuropathy from cycle 4 (20 %) to cycle 8 (43 %) [21]; the most common reason for not progressing to second-line therapy was residua…”
MethodSubbiah, V., Grilley-Olson, J. E., Combest, A. J., Sharma, N., Tran, R. H., Bobe, I., Osada, A., Takahashi, K., Balkissoon, J., Camp, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1114 · Cited by 118
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
Zhang, X., Zang, J., Xu, J., Bai, C., Qin, Y., Liu, K., Wu, C., Wu, M., He, Q., Zhang, S., et al. (2011) · Chest · doi:10.1378/chest.10-2745 · Cited by 71
Metadata
- Authors
- Socinski, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-03-01
- Volume
- 20
- Issue
- 5
- Pages
- 1335-1343
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128082578
- Cited by
- 379
- References
- 19
- FWCI
- 19.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.